Issam S Hamadeh, Tala Shekarkhand, Colin Joseph Rueda, Ross S Firestone, Alice X Wang, Neha Korde, Malin L Hultcrantz, Alexander M Lesokhin, Sham Mailankody, Hani Hassoun, Urvi A Shah, Kylee H Maclachlan, Sridevi Rajeeve, Dhwani Patel, Gunjan L Shah, Michael Scordo, Oscar B Lahoud, David J Chung, Heather J Landau, Sergio A Giralt, Saad Z Usmani, Carlyn Rose Tan
Teclistamab (Tec) is a first-in-class BCMA X CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023...
April 10, 2024: Blood Advances